<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734277</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN066AI</org_study_id>
    <secondary_id>NIAID CRMS ID#: 20722</secondary_id>
    <nct_id>NCT02734277</nct_id>
  </id_info>
  <brief_title>Type 1 Diabetes Extension Study</brief_title>
  <acronym>T1DES</acronym>
  <official_title>Type 1 Diabetes Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, non-interventional study that focuses on the long- term
      effects following participation in select Immune Tolerance Network (ITN) new-onset Type 1
      Diabetes Mellitus (T1DM, T1D) interventional studies focusing on immunomodulatory agents.
      Participants include those that have completed participation in the following trials:
      ClinicalTrials.gov trials NCT00129259 (AbATE), NCT00965458 (T1DAL) and NCT02293837 (EXTEND) .

      This observational study will:

        -  follow participants to determine how long they continue to produce insulin, and

        -  will also assess how changes in the immune system over time relate to the ability to
           produce insulin.

      This information could help design better therapies for type 1 diabetes in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depending upon a participant's level of insulin production, participation may be as short as
      one return visit or a maximum of five years. Evaluation visits will include:

        -  Overall health assessments

        -  Blood and urine collections

        -  Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC).
C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin.
Detectable C-peptide is defined as any value during a MMTT of â‰¥0.15 ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Use in Units per Kilogram Body Weight Per Day</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participant-Reported Major Hypoglycemic Events</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>Major hypoglycemic events are defined as a glucose concentration &lt;55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Undetectable C-Peptide</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>Events of interest include but are not limited to:
Opportunistic and serious infections
Malignancy
Cardiovascular disease
Development of autoimmune disease(s)
Hypersensitivity reactions to unrelated allergens
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Grade 3 or Higher Adverse Events (AEs) of Interest</measure>
    <time_frame>Baseline (Visit 0) to Month 60 (Year 5)</time_frame>
    <description>Events of interest include but are not limited to:
Opportunistic and serious infections
Malignancy
Cardiovascular disease
Development of autoimmune disease(s)
Hypersensitivity reactions to unrelated allergens
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>T1DM</condition>
  <condition>T1D</condition>
  <arm_group>
    <arm_group_label>Group 1: Detectable C-peptide by MMTT</arm_group_label>
    <description>Participants with detectable C-peptide at their:
Last Immune Tolerance Network (ITN) T1DM week 104 study visit,
Last AbATE (NCT00129259) follow-up visit, or
Last ITN066AI T1DES visit
Detectable C-peptide is defined as a value above the lower limit of detection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:Undetectable C-peptide by MMTT</arm_group_label>
    <description>Participants without detectable C-peptide at their:
Last ITN T1DM week 104 study visit,
Last AbATE follow-up visit, or last
ITN066AI T1DES visit
Undetectable C-peptide is defined as a value below the lower limit of detection.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood or urine tests as needed to follow-up on potential long term safety concerns with
           a particular therapeutic agent

        -  Blood and urine samples for additional studies related to your diabetes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus
        (T1DM) studies with immunomodulatory agents as the intervention.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in:

               -  NCT00129259 (AbATE)

               -  NCT00965458 (T1DAL) or

               -  NCT02293837 (EXTEND), and

          -  Ability to sign informed consent/assent (as applicable for children).

        Exclusion Criteria:

          -  Any medical condition that in the opinion of the principal investigator would
             interfere with safe completion of the trial; or

          -  Inability to comply with the study visit schedule and required assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda A. DiMeglio, MD, MPH,MA</last_name>
    <role>Study Chair</role>
    <affiliation>Riley Hospital for Children at Indiana University Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Wesch</last_name>
      <phone>415-476-5984</phone>
      <email>rebecca.wesch@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trudy Esrey</last_name>
      <phone>650-498-4450</phone>
      <email>tesrey@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine: Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Kinney</last_name>
      <phone>303-724-8272</phone>
      <email>MARA.KINNEY@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Ryall</last_name>
      <phone>203-737-4510</phone>
      <email>linda.ryall@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mikhail Smolgovsky</last_name>
      <phone>203-785-6248</phone>
      <email>mikhail.smolgovsky@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>American Newnum</last_name>
      <phone>317-278-7052</phone>
      <email>anewnum@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Hufferd</last_name>
      <phone>317-278-0528</phone>
      <email>rhufferd@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Linda DiMeglio, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care Division of Pediatric Endocrinology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Cabbage</last_name>
      <phone>319-356-4035</phone>
      <email>joanne-cabbage@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Tansey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Krishfield</last_name>
      <phone>617-309-4493</phone>
      <email>Suzanne.Krishfield@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Street</last_name>
      <phone>612-625-9709</phone>
      <email>stree065@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Antoinette Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Beidelschies</last_name>
      <phone>816-760-5918</phone>
      <email>mkbeidelschies@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Dolan</last_name>
      <phone>(816) 760-8876</phone>
      <email>jldolan@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wayne Moore, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Huber</last_name>
      <phone>605-328-8741</phone>
      <email>christina.huber@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kurt Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marli M Olson</last_name>
      <phone>206-342-6943</phone>
      <email>marli@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>https://www.immunetolerance.org/studies/t1d-extended-study-t1des</url>
    <description>ITN T1D Extended Study (T1DES) website</description>
  </link>
  <reference>
    <citation>Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.</citation>
    <PMID>23835333</PMID>
  </reference>
  <reference>
    <citation>Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.</citation>
    <PMID>26193635</PMID>
  </reference>
  <reference>
    <citation>Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.</citation>
    <PMID>24622414</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Glucose Intolerance</keyword>
  <keyword>Prior ITN027AI Study Participants-NCT00129259</keyword>
  <keyword>Prior ITN045AI Study Participants-NCT00965458</keyword>
  <keyword>Prior ITN058AI Study Participants-NCT02293837</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.</ipd_description>
    <ipd_time_frame>After completion of the study.</ipd_time_frame>
    <ipd_access_criteria>Will be available to the public.</ipd_access_criteria>
    <ipd_url>http://www.immport.org/immport-open/public/home/home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

